Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03155178
Other study ID # EM-013953
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date December 5, 2016
Est. completion date April 25, 2017

Study information

Verified date February 2020
Source 3M
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluate persistent antimicrobial effectiveness of chlorhexidine gluconate containing products on abdominal and inguinal sites following a saline and wipe challenge.


Description:

Persistent antimicrobial effectiveness was evaluated by measuring the regrowth of normal skin flora at 48 hours, 72 hours and 96 hours, and the suppression of regrowth relative to post-prep (10-min) at 48 hours, 72 hours and 96 hours.


Recruitment information / eligibility

Status Completed
Enrollment 69
Est. completion date April 25, 2017
Est. primary completion date April 25, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects of any race

- Subjects in good health

- Minimum skin flora baseline requirements on abdomen and groin

Exclusion Criteria:

- Any tattoos, scars, breaks in the skin, or any form of dermatitis, or other skin disorders (including acne) on the applicable test area

- Topical antimicrobial exposure within 14 days prior to screening and treatment days

- Use of systemic or topical antibiotics, steroid medications, or any other products known to affect the normal microbial flora of the skin within 14 days prior to screening and treatment days

Study Design


Related Conditions & MeSH terms

  • Bacterial Recovery of Skin Flora Post-product Application

Intervention

Drug:
3M CHG/IPA Prep
Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
ChloraPrep
Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
3M

Outcome

Type Measure Description Time frame Safety issue
Other Safety Outcome Evaluated by Skin Irritation (Dryness, Edema, Erythema, Rash) Assessment Skin irritation (dryness, edema, erythema, rash) assessed on the test sites using a 0-3 rating scale: 0=no reaction, 1=mild, 2=moderate, 3=severe. Assessed at baseline (pre-treatment) and 10 minutes post-treatment, 48 hours post-treatment, 72 hours post-treatment, 96 hours post-treatment
Primary Measurement of Skin Flora Recovery Post-prep Application The primary measure of persistence is the suppression of regrowth recovery relative to baseline (log10 CFU/cm^2) of skin flora at 3 defined post-treatment sampling times. Baseline, 48-hours post-treatment, 72-hours post-treatment and 96-hours post-treatment
Secondary Change in Skin Flora Relative to 10 Minutes Post-prep Application Log10 CFU/cm^2 regrowth of skin flora, relative to 10-minute post-treatment log10 CFU/cm^2, at 3 defined post-treatment sampling times. 10-minute post-treatment, 48-hours post-treatment, 72-hours post-treatment and 96-hours post-treatment
See also
  Status Clinical Trial Phase
Completed NCT02447497 - In Vivo Patient Preoperative Skin Prep Persistence Phase 2